Venus Remedies is currently trading at Rs 289.30, up by 6.15 points or 2.17% from its previous closing of Rs. 283.15 on the BSE.
The scrip opened at Rs 280.05 and has touched a high and low of Rs 304.90 and Rs 279.50 respectively. So far 139276 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 350.00 on 28-Apr-2014 and a 52 week low of Rs 140.00 on 02-Aug-2013.
Last one week high and low of the scrip stood at Rs 302.80 and Rs 269.75 respectively. The current market cap of the company is Rs 339.14 crore.
The promoters holding in the company stood at 43.99% while Institutions and Non-Institutions held 8.75% and 47.26% respectively.
Venus Remedies has received another patent grant for a novel antibiotic product VRP008 consisting of a carbapenem and a novel aminoglycoside (NCE entity) from European Patent Office (EPO). Pioneering into antimicrobial resistance research, VMRC is engaged in research for this product from the past 8 years.
The product is designed for mixed multi-drug infections for pediatric, geriatric and adult immuno-compromised patients where the risk of adverse events is high and very low amount of doses are required. It is expected to capture a wide range of market sector which is upheaval with antibiotics for wide indications. Besides this, Venus has also received EU patent for its novel product Elores, Potentox, Vancoplus and Achnil.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
